Health and Healthcare
Johnson & Johnson Earnings Just Par for the Course
Published:
Last Updated:
Johnson & Johnson (NYSE: JNJ) reported its first-quarter financial results before the markets opened on Tuesday. The company said that it had $2.06 in earnings per share (EPS) on $20.01 billion in revenue. Consensus estimates had called for EPS of $2.00 on $19.4 billion in revenue. The same period of last year reportedly had $1.83 in EPS on revenue of $17.77 billion.
During the quarter, worldwide consumer sales totaled $3.4 billion, which represented an increase of 5.3% over the prior year, consisting of an operational increase of 1.3% and a positive impact from currency of 4.0%. Domestic sales increased 1.6%, and international sales increased 8.2%, which reflected an operational increase of 1.2% and a positive currency impact of 7.0%.
Worldwide pharmaceutical sales increased 19.4% year over year to $9.8 billion, with an operational increase of 15.1% and a positive impact from currency of 4.3%. Domestic sales increased 9.9%. International sales increased 33.1%, which reflected an operational increase of 22.5% and a positive currency impact of 10.6%.
Worldwide medical devices sales increased 7.5% to $6.8 billion, consisting of an operational increase of 3.2% and a positive currency impact of 4.3%. Domestic sales increased 2.2%, while international sales increased 12.7%, which reflected an operational increase of 4.2% and a positive currency impact of 8.5%.
In terms of guidance, the company expects to see EPS in the range of $8.00 to $8.20 and revenues between $81.0 billion and $81.8 billion for the full year. The consensus estimates are $8.10 in EPS on $81.13 billion in revenue.
Alex Gorsky, board chair and chief executive, commented:
We are pleased with the strong and consistent performance delivered by our colleagues around the world, demonstrated by our sales and EPS growth in the first quarter. Our Pharmaceutical business continues to deliver robust growth and we are pleased with the improvement in our Consumer business. In our Medical Devices businesses, we have areas of leadership and continue to make investments and portfolio choices to improve performance.
The stock was last seen down fractionally at $130.75 a share, with a consensus analyst price target of $149.48 and a 52-week range of $120.95 to $148.32.
24/7 Wall St.Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
